Daily Cardiology Research Analysis
Three studies reshape cardiology from prevention to devices and therapeutics: (1) maternal Western-type diet imprints AP-1–mediated epigenetic memory in endothelial cells that accelerates atherosclerosis in offspring; (2) sacubitril/valsartan provides consistent relative benefit across NT-proBNP levels with greatest absolute gains in the highest-risk patients; (3) a pivotal dual-chamber leadless pacemaker cohort shows 99% implant success and strong learning-curve improvements.
Summary
Three studies reshape cardiology from prevention to devices and therapeutics: (1) maternal Western-type diet imprints AP-1–mediated epigenetic memory in endothelial cells that accelerates atherosclerosis in offspring; (2) sacubitril/valsartan provides consistent relative benefit across NT-proBNP levels with greatest absolute gains in the highest-risk patients; (3) a pivotal dual-chamber leadless pacemaker cohort shows 99% implant success and strong learning-curve improvements.
Research Themes
- Developmental programming and epigenetic memory in atherosclerosis
- Risk stratification and absolute benefit targeting in heart failure therapy
- Leadless pacemaker innovation and procedural learning curves
Selected Articles
1. Maternal high-fat diet exacerbates atherosclerosis development in offspring through epigenetic memory.
Using mouse models and human endothelial cells, the study shows that maternal Western-type diet imprints an AP-1/p300–H3K27ac epigenetic program in aortic endothelium, creating inflammatory memory that accelerates offspring atherogenesis. 27-hydroxycholesterol contributes to memory establishment and acts as a secondary amplifier; blocking AP-1–chromatin binding dampens endothelial inflammation and reduces atherosclerosis.
Impact: This work reveals a mechanistic bridge from maternal nutrition to adult vascular disease via AP-1–mediated chromatin remodeling, offering targets (AP-1/27-hydroxycholesterol) for prevention and therapy.
Clinical Implications: Strengthens rationale for preconception/prenatal cardiometabolic optimization and suggests translational avenues (AP-1 pathway modulators, oxysterol signaling) to mitigate programmed vascular risk.
Key Findings
- Maternal Western-type diet accelerates offspring atherogenesis by inducing AP-1–driven inflammatory chromatin memory in aortic endothelial cells.
- 27-hydroxycholesterol participates in memory establishment and acts as a secondary stimulator, enhancing AP-1/p300 and H3K27ac enrichment.
- Pharmacologic inhibition of AP-1–chromatin binding reduces endothelial inflammatory responses and decreases atherosclerosis in offspring exposed to maternal WD.
Methodological Strengths
- Mechanistic, multi-system approach integrating in vivo mouse models with human endothelial cell assays
- Epigenomic and transcriptional profiling linking AP-1/p300 and H3K27ac to functional vascular phenotypes
Limitations
- Preclinical murine model; human causal validation and dose–response extrapolation are pending
- Specific dietary composition and exposure windows may limit generalizability
Future Directions: Test AP-1/oxysterol pathway modulators in translational models; define critical gestational windows; evaluate reversibility via maternal lifestyle interventions.
Maternal exposure to a Western-type diet (WD) increases the susceptibility of adult offspring to atherosclerosis, partly because fetal endothelial cells (ECs) become dysfunctional and inflamed due to risk factors transmitted via maternal-fetal blood exchange. However, the underlying mechanisms remain unclear. Here we show that maternal WD accelerates atherogenesis in adult offspring mice by regulating chromatin dynamics through activator protein-1 (AP-1) in aortic ECs, inducing inflammatory memory at the chromatin level. We found that 27-hydroxycholesterol is involved in memory establishment and also acts as a secondary stimulator, amplifying the expression of inflammatory factors and enhancing the enrichment of AP-1/p300 and H3K27ac in ECs. Inhibiting AP-1 binding to chromatin reduced the inflammatory response in human umbilical vein ECs from mothers with hypercholesterolemia and decreased atherogenesis in offspring mice exposed to maternal WD. Our findings demonstrate that maternal WD exacerbates EC dysfunction and atherosclerosis in adult offspring by inducing AP-1-associated epigenetic memory, which increases chromatin accessibility to inflammatory genes.
2. Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF.
Pooling PARADIGM-HF and PARAGON-HF, sacubitril/valsartan reduced the composite of HF hospitalization or cardiovascular death consistently across NT-proBNP quintiles. Absolute benefit was largest in the highest NT-proBNP quintile (NNT 16 over 31 months), supporting risk-based prioritization.
Impact: Directly informs patient selection and health system allocation by showing where absolute benefit is greatest while preserving consistent relative efficacy.
Clinical Implications: Treat across NT-proBNP levels, but prioritize initiation and adherence support in patients with high NT-proBNP to maximize absolute event reduction and cost-effectiveness.
Key Findings
- Relative risk reduction with sacubitril/valsartan was consistent across NT-proBNP quintiles (interaction P=0.86).
- Absolute risk reduction and number needed to treat were most favorable in the highest NT-proBNP quintile (NNT 16 over a median 31 months vs 37 in the lowest quintile).
- Event rates rose stepwise with NT-proBNP, enabling risk targeting without loss of relative efficacy.
Methodological Strengths
- Individual patient data pooled from two large, randomized landmark trials across the LVEF spectrum
- Pre-specified composite outcome with consistent statistical approach across quintiles
Limitations
- Secondary, post hoc stratified analysis; not randomized by NT-proBNP levels
- Potential residual confounding and differences in trial populations
Future Directions: Prospective studies to test NT-proBNP–guided initiation/escalation strategies and health-economic impact assessments.
BACKGROUND: Recent trials of new heart failure (HF) treatments suggest the effect of therapy may vary by N-terminal pro-B type natriuretic peptide (NT-proBNP) level. OBJECTIVES: The authors examined the efficacy of sacubitril/valsartan according to NT-proBNP levels in patients with reduced, mildly reduced, and preserved left ventricular ejection fraction (LVEF) enrolled in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting-Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) and PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Receptor Blockers Global Outcomes in HF with Preserved Ejection Fraction). METHODS: Individual patient data from PARADIGM-HF and PARAGON-HF were pooled and participants were divided into categories defined by quintiles of NT-proBNP level. The primary outcome examined was the composite of HF hospitalization or cardiovascular death. RESULTS: Among the 13,195 patients enrolled in both trials, 13,142 (99.6%) had a baseline NT-proBNP level measured. The rate of the primary outcome (per 100 person-years) increased with NT-proBNP levels: quintile 1, 5.9 (95% CI: 5.3-6.5); quintile 2, 7.5 (95% CI: 6.9-8.2); quintile 3, 9.0 (95% CI: 8.2-9.7); quintile 4, 12.0 (95% CI: 11.1-12.9); and quintile 5, 20.8 (95% CI: 19.6-22.2). The relative risk reduction in the primary outcome with sacubitril/valsartan was consistent across NT-proBNP levels: the HR in quintile 1 was 0.79 (95% CI: 0.65-0.96); quintile 2, 0.87 (95% CI: 0.72-1.04); quintile 3, 0.79 (95% CI: 0.66-0.93); quintile 4, 0.85 (95% CI: 0.73-0.99); and quintile 5, 0.86 (95% CI: 0.76-0.97; P for interaction = 0.86). The absolute risk reduction was greatest in NT-proBNP quintile 5; the number needed to treat for the primary outcome over the median follow-up of 31 months was 16 in quintile 5 vs 37 in quintile 1. CONCLUSIONS: The relative risk reductions with sacubitril/valsartan were consistent irrespective of NT-proBNP level in HF patients across the range of LVEF. Consequently, the absolute risk reductions were greatest in patients with higher NT-proBNP levels. (PARADIGM-HF [Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting-Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial]; NCT01035255; and PARAGON-HF [Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Receptor Blockers Global Outcomes in HF with Preserved Ejection Fraction]; NCT01920711).
3. Dual-chamber leadless pacemaker implant procedural outcomes: Insights from the AVEIR DR i2i study.
In 452 patients across 126 implanters, dual-chamber leadless pacing achieved 99% implant success with 11.1% 30-day procedural complications, mainly arrhythmias. With advanced operator experience, procedure times fell by 19–36% and complication-free rates rose from 89% to 98%.
Impact: Provides pivotal real-world procedural benchmarks and a clear learning curve for a disruptive pacing technology likely to change device selection and training.
Clinical Implications: Supports broader adoption of dual-chamber leadless pacing with structured proctoring; centers should anticipate rapid efficiency and safety gains with experience and monitor early arrhythmic complications.
Key Findings
- Implantation success was 99% (446/452) across 126 physicians using a dual-chamber leadless system.
- Procedure times decreased by 19–36% with advanced implanter experience, including fluoroscopy time reductions.
- Thirty-day procedural complications occurred in 11.1% (predominantly arrhythmias), with complication-free rates improving from 89% to 98% as experience increased.
Methodological Strengths
- Large multicenter cohort with standardized procedural metrics and predefined 30-day safety endpoint
- Learning-curve analysis stratified by operator experience
Limitations
- Nonrandomized, single-arm investigational study without active comparator
- Short-term (30-day) complication assessment; longer-term performance and battery/atrial-V sensing durability not reported here
Future Directions: Head-to-head comparisons with transvenous systems; long-term durability, extraction strategies, and cost-effectiveness analyses.
BACKGROUND: Initial results were recently reported for the AVEIR DR i2i study, which involved the percutaneous implantation of a novel dual-chamber leadless pacemaker (LP) system, with right atrial and right ventricular LPs delivering atrioventricular synchronous pacing. OBJECTIVE: The purpose of this study was to evaluate procedural outcomes and learning curve for de novo implantation of the dual-chamber LP (AVEIR DR, Abbott, Abbott Park, IL). METHODS: Implant procedure metrics collected during the study were analyzed, including procedural complications within 30 days of implantation. Procedural outcomes were evaluated according to implanter experience: 1-4 vs 9+ dual-chamber LP implant procedures (ie, initial vs advanced implant experience). RESULTS: De novo dual-chamber LPs were successfully implanted in 446 of 452 patients (99%) by 126 physicians. Mean procedural duration metrics included 90±37 minutes of introducer sheath insertion-to-removal time, 74±32 minutes of dual-chamber procedure duration, 26±17 minutes of right ventricular LP procedure duration, 42±24 minutes of right atrial LP procedure duration, and 20±13 minutes of fluoroscopy duration; between initial and advanced implant experience, there were reductions of 19%-36% (P<.05) in these duration metrics. There were 62 procedural complications in 50 of 452 patients (11.1%) (ie, 88.9% complication free), predominantly involving cardiac arrhythmias (ie, atrial fibrillation/flutter or complete atrioventricular block; 16 of 452 [3.5%]). Freedom from complications significantly improved from 89% to 98% of patients (P<.05) when comparing initial and advanced implant experience. CONCLUSION: In a pivotal investigational study, implantation of a dual-chamber LP system was successful in 99% of patients. Advanced implant experience was accompanied by improvements in procedural outcomes including reduced procedural times (introducer sheath insertion to removal, dual-chamber procedure, ventricular LP and atrial LP procedures, and fluoroscopy) and improved freedom from complications. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05252702.